Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 36
Filter
1.
World J Orthop ; 14(10): 771-775, 2023 Oct 18.
Article in English | MEDLINE | ID: mdl-37970623

ABSTRACT

BACKGROUND: Vancomycin flushing syndrome (VFS), also known as red man syndrome, is an allergic reaction to vancomycin. It typically presents as a rash on the face, neck, and upper torso after intravenous administration of vancomycin. VFS is blamed on rapid intravenous infusion of vancomycin during management and rarely happens after local use. A review of the literature showed that in the last 23 years, 4 such cases have been reported. Here, we add another case of VFS developed after slow local absorption of vancomycin in cement beads. CASE SUMMARY: A 44-year-old male with a known case of hypertension, no history of allergies to medications, and a history of chronic osteomyelitis of the right tibia with discharging sinus over the anterolateral aspect of the leg. The pus culture grew Staphylococcus aureus, which was sensitive to clindamycin and vancomycin. The patient underwent irrigation and debridement with the placement of vancomycin cement beads made from 4 g of vancomycin powder and 40 g of polymethyl methacrylate. Three hours postoperatively, the patient developed a pruritic, erythematous, macular rash predominantly on his face, neck, chest, and lower extremities and to a lesser extent his upper extremities. A diagnosis of VFS was made and was successfully treated with cetirizine (10 mg, oral) and methylprednisolone sodium succinate (125 mg, intravenous). The patient continued to have itching with a facial rash for 12 h with gradual improvement. A decision was made to not remove the beads as the patient continued to improve. Gradually, the rash disappeared after 96 h with no further sequela. CONCLUSION: VFS can occur not only after rapid intravenous injection of vancomycin but also with local release, as in our case. As orthopaedic surgeons routinely use vancomycin with polymethyl methacrylate in chronic osteomyelitis and revision arthroplasty, they should be aware of such a complication occurring.

2.
Front Med (Lausanne) ; 10: 1163817, 2023.
Article in English | MEDLINE | ID: mdl-37484849

ABSTRACT

Background: Anaphylaxis is a potentially fatal condition; in severe cases of anaphylaxis, the cardiovascular system is often heavily involved. Adrenaline (epinephrine) is a cornerstone of the initial treatment of anaphylaxis. The use of epinephrine remains below expectations in clinical practice. Whether the underuse of epinephrine affects the prognosis of patients with anaphylaxis is still unclear. Materials and methods: This retrospective study included patients with anaphylaxis between 2011 and 2020 who were admitted to an emergency department (ED) in Taiwan. All patients were divided into two groups based on the use of epinephrine (or not), and we compared the demographic characteristics, allergens, clinical manifestations, management, and patient outcomes. Results: We reviewed the records of 314 subjects (216 males, 98 females; mean age: 52.78 ± 16.02 years) who visited our ED due to anaphylaxis; 107 (34.1%) and 207 (65.9%) patients were categorized into the epinephrine use group and the non-epinephrine use group, respectively. Arrival via ambulance (p = 0.019), hypotension (p = 0.002), airway compromise (p < 0.001) and altered consciousness (p < 0.001) were the deciding factors for epinephrine use among anaphylactic patients in the ED. The epinephrine use group had higher rates of other inotropic agent usage and fluid challenge. More than 90% of patients received bed rest, steroids, antihistamines, and monitoring. The epinephrine use group had a longer ED length of stay (387.64 ± 374.71 vs. 313.06 ± 238.99 min, p = 0.03) and a greater need of hospitalization. Among all severe symptoms, hypotension was the most tolerated decision factor for not using epinephrine. In this retrospective analysis, some patients with serious anaphylaxis did not experience adverse outcomes or death even without the use of epinephrine at ED admission. Emergent care focuses first on the airway, breathing, and circulation (ABC) and may compensate for the underusage of epinephrine. This could be the reason why epinephrine was underused among patients with anaphylaxis in the ED. Conclusion: In summary, early ABC management continues to play an important role in treating patients with severe anaphylaxis, even when epinephrine is not immediately available in clinical scenarios.

3.
J Pharm Biomed Anal ; 234: 115544, 2023 Sep 20.
Article in English | MEDLINE | ID: mdl-37418870

ABSTRACT

Monoclonal antibody (mAb)-based therapies have been a major advance in oncology patient care, even though they represent a significant healthcare cost. Biosimilars, launched in Europe in 2004 are an economically attractive alternative to expensive originator biological drugs. They also increase the competitiveness of pharmaceutical development. This article focuses on the case of Erbitux® (cetuximab). This anti-EGFR (Epidermal Growth Factor Receptor) monoclonal antibody is indicated for metastatic colorectal cancer (2004) and squamous cell carcinoma of the head and neck (2006). However, despite the expiration of the patent in Europe in 2014 and estimated annual sales of 1.681 million US dollars in 2022, Erbitux® has not yet faced any approved biosimilar challenges in the United States or in Europe. Here, we outline the unique structural complexity of this antibody highlighted by advanced orthogonal analytical characterization strategies resulting in risks to demonstrate biosimilarity, which may explain the lack of Erbitux® biosimilars in the European and US markets to date. The development of Erbitux® biobetters are also discussed as alternative strategies to biosimilars. These biologics offer expected additional safety and potency benefits over the reference product but require a full pharmaceutical and clinical development as for New Molecular Entities.


Subject(s)
Biosimilar Pharmaceuticals , Neoplasms , Humans , United States , Cetuximab/therapeutic use , Biosimilar Pharmaceuticals/therapeutic use , Antibodies, Monoclonal/therapeutic use , Neoplasms/drug therapy , Europe
4.
Front Allergy ; 3: 948380, 2022.
Article in English | MEDLINE | ID: mdl-36238928
5.
Toxins (Basel) ; 14(10)2022 Oct 09.
Article in English | MEDLINE | ID: mdl-36287963

ABSTRACT

Antivenom is an essential treatment for snake envenomation; however, early adverse reactions (EARs) are major limitations to its use. We performed a retrospective cross-sectional study using Ramathibodi Poison Center data (January 2016 to December 2017) to clarify the incidence and severity of EARs following different F(ab')2 antivenoms. Among 1006 envenomed patients, 684 (68%) received antivenom therapy with a total of 1157 doses, mostly green pit viper antivenom. The overall EAR incidence and rate were 22. 5% (154/684) and 15% (173/1157), respectively. The EAR rate following each type of antivenom was >10%, except for Russell's viper antivenom (2.9%); the severe reaction rate was 2.6% (30/1157). Malayan pit viper bites caused a high incidence of EARs (37.8%) and the highest EAR rate (22.3%). Fifty-two cases developed anaphylaxis. All EARs occurred within 2 h after treatment initiation. No deaths were attributed to EARs. The duration of administration was significantly different between doses of antivenom that induced EARs and those that did not. In conclusion, all types and every dose of antivenom should be infused for 30−60 min. Preparation of resuscitation equipment and continuous clinical observation are crucial for at least 2 h after administration, and prompt treatment should be provided when EARs occur.


Subject(s)
Daboia , Poisons , Snake Bites , Animals , Antivenins/adverse effects , Viper Venoms/therapeutic use , Data Analysis , Retrospective Studies , Cross-Sectional Studies , Snake Bites/drug therapy , Snake Bites/epidemiology
6.
Cell Immunol ; 375: 104514, 2022 05.
Article in English | MEDLINE | ID: mdl-35398603

ABSTRACT

Morphine derivatives are clinically important anesthetic and sedative drugs, which often show anaphylactic side effects. Mas-related G-protein coupled receptor member X2 (MRGPRX2) triggers mast cell degranulation, which is important process in anaphylactic reactions. MRGPRX2-HEK293 and LAD2 cell membrane chromatographic (CMC) models were used to screen morphine derivatives binding to MRGPRX2. Furthermore, most morphine derivatives significantly enhanced Ca2+ mobilization. More importantly, thebaine was found to effectively promote histamine release. Thebaine induced the increased release of ß-hexosaminidase and high secretion level of cytokines, confirming that thebaine could further trigger anaphylactic reactions and promote subsequent inflammatory reactions. Moreover, the ability of thebaine inducing degranulation and the release of allergenic mediators in mast cells was significantly decreased after MRGPRX2 knockdown, which proved that MRGPRX2 is the key media for thebaine-induced anaphylactic reactions. Significant hind paw swelling and hypothermia in mice after injecting thebaine suggested that thebaine could trigger anaphylactic reactions in vivo.


Subject(s)
Anaphylaxis , Mast Cells , Nerve Tissue Proteins , Receptors, G-Protein-Coupled , Receptors, Neuropeptide , Thebaine , Anaphylaxis/chemically induced , Animals , Cell Degranulation , HEK293 Cells , Humans , Mice , Mice, Inbred C57BL , Mice, Knockout , Nerve Tissue Proteins/genetics , Receptors, G-Protein-Coupled/genetics , Receptors, G-Protein-Coupled/metabolism , Receptors, Neuropeptide/genetics , Thebaine/adverse effects
7.
Phytother Res ; 36(5): 2197-2206, 2022 May.
Article in English | MEDLINE | ID: mdl-35315143

ABSTRACT

Luteolin is a flavonoid found in many fruits, vegetables, and herbs. The antiinflammatory effects of luteolin have been reported. In this study, the effect of luteolin on allergic diseases and the underlying molecular mechanism were investigated. We found that luteolin inhibits Fc epsilon RΙ (FcεRΙ)- and Mas-related G protein-coupled receptor X2 (MRGPRX2)-mediated mast cells (MCs) activation, including degranulation and release of cytokines in vitro. Moreover, luteolin reduces the degree of swelling and Evans blue exudation of mice paw in a dose-dependent manner. The concentrations of histamine, TNF-α, MCP-1, IL-8, and IL-13 in mice serum are also decreased by luteolin administration. Our study reveals that luteolin can inhibit FcεRΙ- and MRGPRX2-mediated allergic responses in vivo and in vitro, and our results discover luteolin inhibited mast cells mediated anaphylactic reaction by inhibiting the phosphorylation level of PLCγ.


Subject(s)
Anaphylaxis , Calcium Signaling , Anaphylaxis/drug therapy , Animals , Calcium/metabolism , Cell Degranulation , Cell Line , Luteolin/pharmacology , Mast Cells , Mice , Mice, Inbred C57BL , Receptors, G-Protein-Coupled/metabolism
8.
Clin Exp Pharmacol Physiol ; 48(11): 1523-1536, 2021 11.
Article in English | MEDLINE | ID: mdl-34314522

ABSTRACT

Mast cell activation is initiated by two signalling pathways: immunoglobulin E (IgE)-dependent and IgE-independent pathway. It is reported that the IgE-independent type or pseudo-allergy pathway gets activated by G-protein-dependent activation of the mast cell. Recently, adiponectin (APN) receptors, AdipoR1, and AdipoR2 have been identified as G-protein-coupled receptors (GPCRs). Interestingly, APN replenishment is reported to activate the Nrf2/HO-1 signalling axis. However, no study has been performed interlinking the role of APN and the Nrf2/HO-1 signalling axis in pseudo-allergic reaction. In the present study, we evaluated the anti-pseudo-allergic effects of ß-caryophyllene, an FDA-approved food additive, in activating AdipoR1/AdipoR2 and Nrf2/HO-1 axis signalling pathway. Compound 48/80 (C48/80)-induced systemic and cutaneous anaphylaxis-like shock in BALB/c mice was performed to assess the efficacy of ß-caryophyllene (BCP). To assess the effect of BCP in anaphylactic hypotension, mean arterial pressure was measured in Wistar rats. Inhibitory properties of BCP in mast cell degranulation were estimated in rat peritoneal mast cells (RPMCs). ELISA was performed to estimate interleukin (IL)-6, tumour necrosis factor (TNF), IL-1ß, IgE, ovalbumin (OVA)-IgE and APN and western blotting for protein expression of Nrf2/HO-1 and AdipoR1-AdipoR2. BCP dose-dependently inhibited systemic and cutaneous anaphylaxis-like shock induced by C48/80. BCP dose-dependently inhibited the mast cell degranulation followed by inhibition of histamine release. Also BCP dose-dependently activated the Nrf2/HO-1 and AdipoR1-AdipoR2 signalling axis pathway. Moreover, BCP reversed the drop in blood pressure when the haemodynamic parameters were accessed. Our findings suggest that BCP is a potent AdipoR1/AdipoR2-Nrf2/HO-1 axis pathway agonist that may suppress the IgE-independent pathway towards allergic response to secretagogues.


Subject(s)
p-Methoxy-N-methylphenethylamine
9.
Rev. mex. anestesiol ; 44(2): 105-109, abr.-jun. 2021. tab
Article in Spanish | LILACS-Express | LILACS | ID: biblio-1347725

ABSTRACT

Resumen: Introducción: La anafilaxia perioperatoria constituye una condición clínica potencialmente letal. La causa más frecuente se atribuye a los bloqueadores neuromusculares. Objetivo: Identificar la incidencia de reacciones anafilácticas secundarias al uso de bloqueadores neuromusculares. Material y métodos: Se realizó una investigación descriptiva, observacional, de corte transversal para evaluar la incidencia de reacciones anafilácticas secundarias al uso de bloqueantes neuromusculares. El estudio se realizó en el Hospital «Hermanos Ameijeiras¼ en el período comprendido entre enero de 2016 y diciembre de 2018. Resultados: Del total de intervenciones quirúrgicas electivas, 3,431 requirieron anestesia general y el uso de bloqueadores neuromusculares. Predominó el sexo femenino en 75% de los casos, el grupo etario de 60 años y más con 68 pacientes (32.7%), el estado físico ASA II, 98 pacientes (41.1%). La media del IMC fue de 22.7 ± 1.14. La media del tiempo quirúrgico fue de 190 ± 42.5 min. De todos los fármacos el más utilizado fue el atracurio en 90 pacientes (43.3%) seguido del vecuronio 79 (38.0%) y el rocuronio 39 (18.8%). El número de eventos adversos fue escaso. Sólo se encontraron cuatro, dos con atracurio (50%), uno con rocuronio y uno con vecuronio 25% respectivamente. Conclusiones: Se constató la presencia de reacciones anafilácticas por el uso de bloqueadores neuromusculares, mismas que se manifestaron en un corto período al inicio de la inducción. El atracurio presentó la mayor frecuencia y todas fueron de intensidad leve.


Abstract: Introduction: Perioperative anaphylaxis is a potentially lethal clinical condition. The most frequent cause is attributed to neuromuscular blockers. Objective: To identify the incidence of anaphylactic reactions secondary to the use of neuromuscular blockers. Material and methods: A descriptive, observational, cross-sectional investigation was conducted to assess the incidence of anaphylactic reactions secondary to the use of neuromuscular blockers. The study was carried out at the «Hermanos Ameijeiras¼ Hospital, in the period between january 2016 and december 2018. Results: Of the total elective surgical interventions, 3,431 required general anesthesia and the use of neuromuscular blockers. The female sex predominated with 75%, the age group of 60 years and over with 68 patients (32.7%), ASA II physical condition, 98 patients (41.1%). The average BMI was 22.7 ± 1.14. The mean surgical time was 190 ± 42.5 min. Of all the drugs the most used was atracurium in 90 patients (43.3%), followed by vecuronium 79 (38.0%) and rocuronium 39 (18.8%). The number of adverse events was low. Only four were found, two with atracurium (50%), one with rocuronium and one with 25% vecuronium respectively. Conclusions: The presence of anaphylactic reactions was observed with the use of neuromuscular blockers, which occurred in a short period at the beginning of induction. The atracurium presented the highest frequency and all were of mild intensity.

10.
Article in English | MEDLINE | ID: mdl-32727338

ABSTRACT

AIM: Investigating about the history of allergies and discovery of the histamine's role in the immune response through historical references, starting with ancient anecdotes, analysing the first immunization attempts on animals to understand its importance as the anaphylaxis mediator. Moreover, we shortly resume the most recent discoveries on mast cell role in allergic diseases throughout the latest updates on its antibody-independent receptors. METHODS: Publications, including reviews, treatment guidelines, historical and medical books, on the topic of interest were found on Medline, PubMed, Web of Knowledge, Web of Science, Google Scholar, Elsevier's (EMBASE.comvarious internet museum archives. Texts from the National Library of Greece (Stavros Niarchos Foundation), from the School of Health Sciences of the National and Kapodistrian University of Athens (Greece). We selected key articles which could provide ahistorical and scientific insight into histamine molecule and its mechanism of action's discovery starting with Egyptian, Greek and Chinese antiquity to end with the more recent pharmacological and molecular discoveries. RESULTS: Allergic diseases were described by medicine since ancient times, without exactly understanding the physio-pathologic mechanisms of immuno-mediated reactions and of their most important biochemical mediator, histamine. Researches on histamine and allergic mechanisms started at the beginning of the 20th century with the first experimental observations on animals of anaphylactic reactions. Histamine was then identified as their major mediator of many allergic diseases and anaphylaxis, but also of several physiologic body's functions, and its four receptors were characterized. Modern researches focus their attention on the fundamental role of the antibody-independent receptors of mast cells in allergic mechanisms, such as MRGPRX2, ADGRE2 and IL-33 receptor. CONCLUSION: New research should investigate how to modulate immunity cells activity in order to better investigate possible multi-target therapies for host's benefits in preclinical and clinical studies on allergic diseases in which mast cells play a major role.


Subject(s)
Allergens/immunology , Histamine/immunology , Hypersensitivity/immunology , Immunity, Cellular/immunology , Mast Cells/immunology , Allergens/metabolism , Anaphylaxis/drug therapy , Anaphylaxis/immunology , Anaphylaxis/metabolism , Animals , Histamine/metabolism , Histamine Antagonists/pharmacology , Histamine Antagonists/therapeutic use , History, 20th Century , History, 21st Century , History, Ancient , History, Medieval , Humans , Hypersensitivity/drug therapy , Hypersensitivity/metabolism , Immunity, Cellular/drug effects , Mast Cells/drug effects , Mast Cells/metabolism , Nerve Tissue Proteins/immunology , Receptors, G-Protein-Coupled/immunology , Receptors, Neuropeptide/immunology
11.
SA J Radiol ; 24(1): 1841, 2020.
Article in English | MEDLINE | ID: mdl-32537252

ABSTRACT

BACKGROUND: Emergencies in the radiology department may arise in critically ill patients who are brought to the department for imaging, interventional procedures or as a result of adverse reactions to contrast media used for imaging. Adverse reactions to contrast media range from minor to severe life-threatening effects and initial, prompt management decreases complications. Radiology staff must possess knowledge of the management of anaphylactic or anaphylactoid contrast reactions and cardiopulmonary arrest (CPA) as they are likely to be the first responders. OBJECTIVES: To determine the knowledge and practices amongst radiologists, radiology residents and radiographers in the management of CPA and adverse reactions to contrast media. METHOD: This cross-sectional study was performed between March and August 2016 at Kenyatta National Hospital using a questionnaire. RESULTS: Eighty participants were enrolled. None answered all the questions correctly, with only 55% of radiologists, 35% of residents and 39% of radiographers scoring above 50%. The majority (82%) of participants had adequate knowledge regarding the symptoms, signs and risk factors of adverse reactions to contrast media; however, only 30% knew that intravenous epinephrine is the recommended therapy for a severe anaphylactic reaction. Shortcomings in terms of adequate training were found in this study, with the majority of respondents having not attended any life support course in the preceding 5 years. CONCLUSION: Health providers within the radiology unit had knowledge about identifying both mild and severe symptoms of anaphylactic reactions. However, there were knowledge gaps regarding the management of these reactions.

12.
J Clin Pathol ; 73(5): 250-256, 2020 May.
Article in English | MEDLINE | ID: mdl-31831575

ABSTRACT

Post-anaphylaxis mast cell anergy (PAMA), commonly referred to as 'empty mast cell (MC) syndrome', is a state of temporary loss of cutaneous MC reactivity in the immediate aftermath of anaphylaxis. Data relating to this condition are sparse and the incidence rate is currently unknown. PAMA has been described only in a few published case reports in the context of hymenoptera venom allergy and perioperative anaphylaxis. Best practice guidelines regarding optimal timing for performing skin tests postanaphylaxis are largely based on expert opinion, and allergy work-up has been recommended after 4-6 weeks postanaphylaxis to avoid false-negative results.This article provides a review of clinical literature surrounding PAMA, critically evaluates intracellular events in MCs from in vitro data and hypothesises regarding plausible immune mechanisms. There are no published data to directly explain molecular mechanisms underlying this phenomenon. Although not evidence based, PAMA has been attributed to depletion of MC granules following anaphylaxis. It is also plausible that exposure to high allergen concentrations in anaphylaxis can induce a temporary shift in MCs towards dominance of inhibitory signalling pathways, thus contributing to a state of transient hyporesponsiveness observed in some patients. Other potential contributory factors for reduced MC reactivity include downregulation of FcεRI expression, cross-linking of FcεRI to the inhibitory, low-affinity IgG receptors and administration of pharmacotherapeutic agents for anaphylaxis treatment. It is likely that this interesting phenomenon can be explained by a combination of these proposed mechanisms in addition to other genetic/host factors that have not yet been identified.


Subject(s)
Anaphylaxis/physiopathology , Immunologic Deficiency Syndromes/etiology , Mast Cells/immunology , Anaphylaxis/diagnosis , Anaphylaxis/immunology , False Negative Reactions , Humans , Immunologic Deficiency Syndromes/diagnosis , Skin Tests
13.
Expert Rev Vaccines ; 18(10): 993-1015, 2019 10.
Article in English | MEDLINE | ID: mdl-31594419

ABSTRACT

Introduction: Three major advances have led to increase in length and quality of human life: increased food production, improved sanitation and induction of specific adaptive immune responses to infectious agents (vaccination). Which has had the most impact is subject to debate. The number and variety of infections agents and the mechanisms that they have evolved to allow them to colonize humans remained mysterious and confusing until the last 50 years. Since then science has developed complex and largely successful ways to immunize against many of these infections.Areas covered: Six specific immune defense mechanisms have been identified. neutralization, cytolytic, immune complex, anaphylactic, T-cytotoxicity, and delayed hypersensitivity. The role of each of these immune effector mechanisms in immune responses induced by vaccination against specific infectious agents is the subject of this review.Expertopinion: In the past development of specific vaccines for infections agents was largely by trial and error. With an understanding of the natural history of an infection and the effective immune response to it, one can select the method of vaccination that will elicit the appropriate immune effector mechanisms (designer vaccines). These may act to prevent infection (prevention) or eliminate an established on ongoing infection (therapeutic).Literature search: The primary literature source is Pub Med. Secondary source is Wikipedia.


Subject(s)
Immunization , Vaccination , Vaccines/immunology , Adaptive Immunity , Animals , Antigen-Antibody Complex , Databases, Factual , Drug Design , Humans , Hypersensitivity , Immunity, Innate , Immunologic Techniques , Vaccination/classification , Vaccines/classification , Viruses
14.
Orv Hetil ; 160(38): 1514-1518, 2019 Sep.
Article in Hungarian | MEDLINE | ID: mdl-31537093

ABSTRACT

Immunglobulin E (IgE)-based, irregularly recurring, severe anaphylactic reactions occurred in a 50-year-old European white male patient suffering also from Crohn's disease. On the base of immunologic laboratory tests concerning the mechanism of the phenomenon, the idea arose whether molecules derived for certain microbial derivatives could enter the blood circulation via the damaged bowel walls in the patient with Crohn's disease and they might act as allergens. The microbial analysis diagnosed atypical Staphylococcus in the stool. The serum level of IgE was very high. The concomitant use of targeted antibiotics and anti-allergy and immunosuppressive agents resulted in a complete remission during a couple of months. Not only Crohn's disease has improved, but also the total serum IgE level has decreased significantly, and the unpredictable anaphylactic attacks have been completely eliminated. In Crohn's disease, the anaphylactic complications induced by atypical microbial allergens (e.g., derivatives of Staphylococcus) can be effectively treated after the recognition of this pathological mechanism. This is the first description of such a pathologic state. Orv Hetil. 2019; 160(38): 1514-1518.


Subject(s)
Anaphylaxis/drug therapy , Anti-Allergic Agents/therapeutic use , Anti-Bacterial Agents/therapeutic use , Crohn Disease/complications , Immunoglobulin E/blood , Immunosuppressive Agents/therapeutic use , Staphylococcus , Anaphylaxis/diagnosis , Anaphylaxis/microbiology , Humans , Male , Middle Aged , Remission Induction , Treatment Outcome
15.
World J Hepatol ; 11(3): 318-329, 2019 Mar 27.
Article in English | MEDLINE | ID: mdl-30967909

ABSTRACT

BACKGROUND: Most patients with hydatid cysts are asymptomatic, and they are diagnosed incidentally during radiological evaluations performed for other reasons. However, some patients develop symptoms and complications due to cyst size, location, and the relationship between the cyst and adjacent structures. The most serious complications that can occur are rupture of the cysts into the biliary tract, vascular structures, hollow viscus, and peritoneal cavity. We aimed to describe the management of four cases of intraperitoneal rupture of hydatid cysts. CASE SUMMARIES: Four patients aged between 27 and 44 years (two men and two women) were admitted to our clinic with sudden abdominal pain (n = 4), hypotension (n = 3), and anaphylaxis (n = 2). Three of the perforated cysts were located in the liver, and one was located in the spleen. Two patients developed cyst rupture after minor trauma, and the other two developed spontaneous rupture. Enzyme-linked immunosorbent assay IgG results were positive for two patients and negative for the other two. All patients received albendazole treatment after surgical intervention (range: 2-6 mo). Two patients developed hepatic abscesses requiring drainage; one of these patients also developed hydatid cyst recurrence during postoperative follow-up (range: 25-80 mo). CONCLUSION: Intraperitoneal rupture is a life-threatening complication of hydatid cysts. It is important to manage patients with surgical intervention as soon as possible with aggressive medical treatment for anaphylactic reactions.

16.
Allergol Int ; 68(3): 316-320, 2019 Jul.
Article in English | MEDLINE | ID: mdl-30737115

ABSTRACT

BACKGROUND: Anaphylaxis is a severe and potentially fatal allergic response. Early-life exposure to rural environments may help protect against allergic reaction. This study assesses urban/rural differences by age and race/ethnicity in emergency department (ED) pediatric visit rates for food-induced anaphylaxis. METHODS: This observational study examined 2009-2014 inpatient and ED data from New York and Florida, using ICD-9-CM diagnostic code (995.6) to identify food-induced anaphylaxis cases <18 y/o. Primary predictor of interest was urban/rural setting, with race/ethnicity and age also evaluated. Associations between ED visit rates and urban/rural setting were evaluated by multivariable hierarchical negative binomial regression with state and year fixed effects. RESULTS: ED visit rates (per 100,000) for food-induced anaphylaxis were 12.31 and 4.60 in urban and rural settings, respectively. Rates were highest among Blacks (15.26) younger urban children (17.29) and older rural children (6.99). Compared to rural, urban children had significantly higher anaphalaxis ED visit rates (IRR 2.77). CONCLUSIONS: Food-induced anaphylaxis ED visit rates were highest among younger urban children and Black children, with a notable contrast in age distribution between urban and rural rates. Higher urban rates may be attributed to Hygiene Hypothesis, though racial, economic and emergency care access disparities may also influence these outcomes.


Subject(s)
Anaphylaxis/epidemiology , Emergency Service, Hospital/statistics & numerical data , Food Hypersensitivity/epidemiology , Adolescent , Anaphylaxis/diagnosis , Anaphylaxis/etiology , Child , Child, Preschool , Female , Florida/epidemiology , Food Hypersensitivity/complications , Food Hypersensitivity/diagnosis , Health Status Disparities , Humans , Incidence , Infant , Infant, Newborn , Male , New York/epidemiology , Rural Population/statistics & numerical data , Urban Population/statistics & numerical data
17.
Toxicol Appl Pharmacol ; 366: 46-53, 2019 03 01.
Article in English | MEDLINE | ID: mdl-30684531

ABSTRACT

The classical mast cells degranulation pathway is mediated by FcεRI aggregation and varies in strength among subjects. Dehydroandrographolide (DA) is one of principal components of Andrographis paniculata (Burm.f.) Nees (family: Acanthaceae) and considered the main contributors of its therapeutic properties, such as anti-tumor. In this study, inhibition of IgE-mediated anaphylactic reactions and anti-inflammatory potential of DA were investigated. The anti-anaphylactic activity of DA was investigated using skin swelling and extravasation assays in vivo and mast cell degranulation assay in vitro. The release of cytokines was measured using ELISA kits. Human Phospho-Kinase Array kit and western blotting were used to explore the related molecular signaling pathways. DA inhibited IgE-mediated mast cell activation, including degranulation and release of cytokines in vitro. Moreover, DA reduced the degree of swelling and Evans blue exudation of mice paw in a dose-dependent manner by inhibiting mast cell degranulation. DA obviously reduced the concentrations of histamine, TNF-α, MCP-1, IL-8, IL-13, and IL-4 in mice serum and inhibited IgE-mediated anaphylactic reactions as a potential P-PLCγ inhibitor. Our study reveals that DA can inhibit allergic responses in vivo and in vitro, and it may be regarded as a novel P-PLCγ inhibitor for preventing mast cell-immediate and delayed allergic diseases.


Subject(s)
Anaphylaxis/drug therapy , Anti-Allergic Agents/pharmacology , Calcium Signaling/drug effects , Diterpenes/pharmacology , Histamine Release/drug effects , Immunoglobulin E/immunology , Mast Cells/drug effects , Anaphylaxis/immunology , Anaphylaxis/metabolism , Animals , Cell Degranulation/drug effects , Cell Line , Cytokines/metabolism , Disease Models, Animal , Enzyme Inhibitors/pharmacology , Humans , Male , Mast Cells/immunology , Mast Cells/metabolism , Mice, Inbred C57BL , Ovalbumin , Phospholipase C gamma/antagonists & inhibitors , Phospholipase C gamma/metabolism
18.
J Clin Pathol ; 72(3): 221-224, 2019 Mar.
Article in English | MEDLINE | ID: mdl-29305517

ABSTRACT

AIM: To record the level of allergy teaching occurring in UK medical schools. The UK has experienced an 'allergy epidemic' during the last 3-4 decades. Previous government reviews have emphasised the importance of allergy education and training, treating common allergies in primary care with referral pathways to a specialist and the creation of regional networks. It is acknowledged that the delivery of allergy teaching in UK medical schools is variable, despite the well-recognised need. METHODS: All consultant members of the British Society for Allergy and Clinical Immunology involved in teaching medical students were invited to partake in qualitative research, employing an online questionnaire for data collection. Participants were asked to comment on the format of the allergy teaching delivered, the student participation and the clinical opportunities provided. Students were recruited to complete a similar survey as supporting evidence. RESULTS: 44 responses were collected, representing 64.7% of medical schools in the UK. Clinical allergy placements were compulsory in 31.8% of medical schools that responded. In 36.4%, it was reported that less than 10% of students had an opportunity to take an independent history from a patient with allergic disease, or practise using an epinephrine autoinjector. 90.9% responded that an allergy rotation was not offered to final year students. CONCLUSIONS: Allergy undergraduate teaching is suboptimal and heterogeneous in UK medical schools and there is a real need for standardisation as a means to enhance quality of care.


Subject(s)
Allergy and Immunology/education , Education, Medical, Undergraduate/methods , Hypersensitivity , Curriculum , Education, Medical, Undergraduate/standards , Humans , United Kingdom
19.
Clin Case Rep ; 6(7): 1276-1277, 2018 Jul.
Article in English | MEDLINE | ID: mdl-29988657

ABSTRACT

Gonadotropin-releasing hormone (GnRH) analogues represent the gold standard treatment for precocious puberty. Allergic-type reactions in children due to this type of treatment are very rare. However, caregivers should be aware of the potential GnRH analogue systemic reactions.

20.
Int Med Case Rep J ; 11: 125-127, 2018.
Article in English | MEDLINE | ID: mdl-29872353

ABSTRACT

BACKGROUND: Drug-induced hypersensitivity reaction is of great clinical significance in therapeutics. The objective of this reporting of two cases is to show that anaphylaxis reaction can occur with pantoprazole. CASE SUMMARIES: A 38-year-old female reported to the emergency ward in a critical condition, with a history of periorbital edema, edema of the skin, pruritus, nausea, vomiting, and difficulty breathing 20 minutes after ingestion of a pantoprazole 40 mg tablet. A 32-year-old female reported to the emergency ward in a critical condition, with complaints of rashes all over the body, itching on the whole body, and swollen lips and eyes after ingestion of a pantoprazole 40 mg tablet. CONCLUSION: It is necessary for all health care providers to know that pantoprazole can cause anaphylaxis, which is a life-threatening reaction, and to be cautious while prescribing it.

SELECTION OF CITATIONS
SEARCH DETAIL
...